Viking Therapeutics VKTX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -70%-55.6pp | -47.3%-29.4pp | -29.2%-13.7pp | -20%-5.2pp | -14.4%+3.1pp | |
| Efficiency | ||||||
| Asset turnover | 0×— | 0×— | 0×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 5.7×-38.5× | 9.3×-23.8× | 28.3×-8.1× | 25.9×-11.8× | 44.2×+14.8× | |
| Per Share | ||||||
| Book value per share | $4.34-42.5% | $5.67-29.7% | $6.35-22.8% | $7.09-15.0% | $7.56-16.3% | |
| Valuation | ||||||
| Market capitalization | $3.76B+38.7% | $3.98B-11.3% | $2.96B-57.7% | $3.03B-44.8% | $2.71B-68.0% | |
| Price / book | 7.5×+4.3× | 6.2×+1.1× | 4.1×-3.5× | 3.8×-2.1× | 3.2×-5.9× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Viking Therapeutics's ratios come from?
- Every ratio is computed from Viking Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.